TLTFF (Theralase Technologies) Total Assets: $2.84 Mil (As of Mar. 2026)


TLTFF Theralase Technologies Inc TLTFF
46 GF Score
Price $0.17
GF Value $0.13
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Theralase Technologies Total Assets?

Theralase Technologies TLTFF +1.22% 46 Total Assets is $2.84 Mil as of Mar. 2026. GuruFocus rates TLTFF with a GF Score™ of 46/100 and a GF Value™ of $0.13 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Theralase Technologies's Total Assets for the quarter that ended in Mar. 2026 was $2.84 Mil.

During the past 12 months, Theralase Technologies's average Total Assets Growth Rate was 2.10% per year. During the past 3 years, the average Total Assets Growth Rate was 7.70% per year. During the past 5 years, the average Total Assets Growth Rate was 9.60% per year. During the past 10 years, the average Total Assets Growth Rate was 0.50% per year.

During the past 13 years, Theralase Technologies's highest 3-Year average Total Assets Growth Rate was 1376.40%. The lowest was -28.20%. And the median was 3.40%.

Total Assets is connected with ROA %. Theralase Technologies's annualized ROA % for the quarter that ended in Mar. 2026 was -112.05%. Total Assets is also linked to Revenue through Asset Turnover. Theralase Technologies's Asset Turnover for the quarter that ended in Mar. 2026 was 0.04.

Theralase Technologies  (OTCPK:TLTFF) Total Assets Explanation

Total Assets is connected with ROA %.

Theralase Technologies's annualized ROA % for the quarter that ended in Mar. 2026 is

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-3.008/( (2.534+2.835)/ 2 )
=-3.008/2.6845
=-112.05 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) data.

In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.

Total Assets is linked to total revenue through Asset Turnover.

Theralase Technologies's Asset Turnover for the quarter that ended in Mar. 2026 is

Asset Turnover
=Revenue (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=0.097/( (2.534+2.835)/ 2 )
=0.097/2.6845
=0.04

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.

Theralase Technologies Total Assets Related Terms

Theralase Technologies Total Assets Historical Data

* Premium members only.

The historical data trend for Theralase Technologies's Total Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Theralase Technologies Total Assets Chart

Theralase Technologies Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.65 3.06 2.44 2.28 2.53

Theralase Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.06 2.21 2.17 2.53 2.84
TLTFF
46GF Score
Theralase Technologies Inc TLTFF
Total Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Theralase Technologies Total Assets Calculation

Total Assets are all the assets a company owns.

From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.

Theralase Technologies's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as

Total Assets=Total Equity (A: Dec. 2025 )+Total Liabilities (A: Dec. 2025 )
=1.289+1.245
=2.53

Theralase Technologies's Total Assets for the quarter that ended in Mar. 2026 is calculated as

Total Assets=Total Equity (Q: Mar. 2026 )+Total Liabilities (Q: Mar. 2026 )
=1.421+1.414
=2.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Assets →
What does a Total Assets of $2.84 Mil mean?
Theralase Technologies (TLTFF) has a Total Assets of $2.84 Mil as of Mar. 2026. The total amount of assets as recorded on a company's balance sheet. View historical data on Theralase Technologies and its competitors.
Is Theralase Technologies' Total Assets too high?
Theralase Technologies' current Total Assets is $2.84 Mil. Overall, Theralase Technologies has a GF Score™ of 46/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Theralase Technologies' Total Assets compare to ABT and SYK?
Theralase Technologies' Total Assets of $2.84 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Medical Devices & Instruments company?
A good Total Assets depends on the Medical Devices & Instruments industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Theralase Technologies and its competitors. Theralase Technologies's current Total Assets is $2.84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Theralase Technologies stock overvalued right now?
Based on GuruFocus' analysis, Theralase Technologies (TLTFF) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.13, compared to a current price of $0.17 — trading 28.1% above its estimated fair value. The current Total Assets is $2.84 Mil. Theralase Technologies' overall GF Score™ is 46/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Theralase Technologies (TLTFF), the current Total Assets is $2.84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Theralase Technologies (TLTFF) Overvalued in 2026?

Based on GuruFocus' analysis, Theralase Technologies stock appears to be overvalued. The current stock price of $0.17 is trading 28.1% above its estimated GF Value™ of $0.13. GuruFocus considers Theralase Technologies to be Modestly Overvalued.

Key valuation signals for TLTFF:

  • Total Assets: $2.84 Mil
  • GF Value™: $0.13 vs. price of $0.17 (28.1% above fair value)
  • GF Score™: 46/100 with 4 warning signs

No single metric tells the full story. See the TLTFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Theralase Technologies Business Description

Other Exchanges TTX:GermanyTLT:Canada
Address 41 Hollinger Road, Toronto, ON, CAN, M4B 3G4
Theralase Technologies Inc brings CLT to patients and personalized ACT to patients based on individual tissue characteristics. It is two separate reportable operating divisions; the Drug Division and the Device Division. The Drug Division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs), and activates them with proprietary and patent-pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The Device Division designs develops, manufactures, and markets proprietary super-pulsed laser technology indicated and cleared by Health Canada and the Food and Drug Administration (FDA) for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions.
46GF Score

Get the complete analysis for TLTFF

Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.17
Price
$0.13
GF Value